Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 12,009 shares at $25.03 ($294K) on 2024-04-11, disclosed to the SEC on 2024-04-15.
Scheduled sale ($294k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 649 | $16K | 5.5% |
| 2 | $25.03 | 5,045 | $126K | 42.9% |
| 3 | $25.03 | 5,045 | $126K | 42.9% |
| 4 | $19.94 | 1,190 | $24K | 8.1% |
| 5 | $20.68 | 80 | $2K | 0.6% |
| Total | $24.49 avg | 12,009 |
| $294K |
| 100% |
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |